Gedeon Richter Plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat) (17 March 2011)
The patents are not invalid for added matter except in relation to the 3mg loading point, which is addressed by conditional amendment. The patents are not obvious over the cited prior art. The claims, properly construed, do not exclude enteric coated formulations if they satisfy the dissolution test. All other added matter and obviousness attacks fail.
- Citation
- [2011] EWHC 583 (Pat)
- Parties
- Claimant: Gedeon Richter plc; Defendant: Bayer Schering Pharma AG
- Jurisdiction
- England and Wales
- Judgment Date
- 17 March 2011
- Procedural Posture
- Patent Revocation Action / High Court Trial Judgment
- Outcome
- Patents held valid subject to amendment; revocation refused.
- Legal Topics
- Patent Validity, Obviousness, Added Matter, Pharmaceutical Patents, Claim Construction
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Gedeon Richter plc
Claimant
Bayer Schering Pharma AG
Defendant
Procedural Posture
Patent Revocation Action / High Court Trial Judgment
Legal Issues
- 1 Whether European Patent (UK) Nos. 1,380,301 and 1,598,069 are invalid for obviousness over prior art
- 2 Whether the patents contain added matter beyond the parent application
- 3 Proper construction of the claims regarding enteric coated formulations
Ratio Decidendi
The patents are not invalid for added matter except in relation to the 3mg loading point, which is addressed by conditional amendment. The patents are not obvious over the cited prior art. The claims, properly construed, do not exclude enteric coated formulations if they satisfy the dissolution test. All other added matter and obviousness attacks fail.
Court Disposition
Patents held valid subject to amendment; revocation refused.
Orders
- Unconditional and conditional amendments to the patents allowed as specified.
- All other claims for revocation dismissed.
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment